At a glance
| Molecular type | Large follistatin protein precursor |
|---|---|
| Processing | FS344 precursor yields mature FS315 |
| Ligands | Activin family, including myostatin |
| Human intervention studied | AAV-mediated gene transfer |
| Main evidence limit | Very small uncontrolled early trials |
Overview
Follistatin is a relatively large binding protein, not a short conventional peptide. The FS344 precursor is processed to a mature circulating form commonly called FS315. By neutralizing growth-regulating ligands, it can influence muscle biology and reproductive endocrine signaling. Human interest arose from the ability of myostatin-pathway inhibition to increase muscle size in experimental systems. A small Becker muscular dystrophy study delivered a gene encoding FS344 into muscle using an adeno-associated viral vector. This is a very different intervention from injecting a purchased follistatin powder: the site, duration, tissue expression, molecular processing, and safety surveillance are not interchangeable.
How it works
Follistatin binds selected TGF-beta superfamily ligands, including activins and myostatin, preventing their interaction with signaling receptors. Blocking myostatin can reduce a restraint on muscle growth, but follistatin is not specific to that one pathway. Activin signaling also participates in reproductive and other tissue functions. Molecular isoform and tissue distribution therefore matter, as do the distinction between transient protein administration and sustained expression after gene transfer.
What the Becker muscular dystrophy trial tested
Six participants received intramuscular delivery of an AAV vector encoding FS344. Some improved on the six-minute walk test and muscle biopsies showed changes consistent with the proposed action. The study was early phase, small, and uncontrolled. It cannot determine the magnitude of benefit reliably or exclude uncommon and delayed adverse effects.
Supporting sources [1]
Why muscle size and strength can diverge
The discovery that myostatin-deficient mice develop markedly enlarged muscles supplied a strong biological rationale for this field. However, genetic loss in mice, experimental ligand blockade, and treatment of human muscle disease are separate interventions. Functional outcomes, tissue quality, disease progression, and off-target effects must be assessed rather than inferred from size alone.
Supporting sources [2]
Broader signaling and delivery risks
Follistatin also binds activins, so reproductive and other systemic effects are relevant uncertainties. Gene delivery additionally introduces vector-related risks and prolonged expression that cannot be equated with short-lived protein exposure. Conversely, favorable observations in a monitored gene-therapy cohort do not establish the purity, sterility, or safety of a vendor’s injected protein.
Does FS344 research validate a follistatin vial?
No. The human study used a specified genetic construct, delivery system, patient group, and follow-up protocol. Engineered follistatin fusion proteins in animal experiments are yet another preparation. No approved US follistatin-344 medicine or established healthy-person muscle-enhancement indication follows from these studies.
Reading this profile
Jurisdiction: United States: experimental protein/gene-therapy research; no approved follistatin-344 injectable medicine.. Molecular class: Follistatin protein precursor; studied through experimental gene transfer.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. ↗Original research · Checked 2026-10-27
- Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. ↗Original research · Checked 2026-10-27
- Engineered follistatin therapeutic in experimental muscle regeneration ↗Original research · Checked 2026-10-27